How Immutep’s Eftilagimod Alfa Dose Unlocks New Hope in Breast Cancer

• Phase II AIPAC-003 trial shows strong response rates in heavily pretreated metastatic breast cancer
• 30 mg eftilagimod alfa selected as optimal biological dose following FDA Project Optimus guidelines
• Combination therapy with paclitaxel activates immune biomarkers including lymphocyte count and interferon-gamma
• Higher 90 mg dose linked to increased toxicity and injection site reactions